WaveMan
WaveMan · Company
QTTB · Q32 Bio Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

QTTB Q32 Bio (QTTB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001661998
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
45
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $149.9K priced

What the filings say about QTTB

Insiders, 180 days
+$29.7M net bought
2 buyers · 3 sellers · 0% of sales under a 10b5-1 plan

Q32 Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Q32 Bio Inc. insiders bought a net $29.7M of stock across 21 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Morrison Jodie Pope
CEO
SELL
2026-10-14 SECtraded 2026-10-06
3,221
$26.8K
+11.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 25, 2026.
  • The trade is 0.9% of the 340,038 shares held after it.
  • 2 other insiders sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Morrison Jodie Pope sold about $26.8K of QTTB on Oct 6, 2026; 2 other insiders sold within 30 days and 45 funds added in the latest 13F quarter.
Violette Shelia M.
Chief Scientific Officer
SELL
2026-10-14 SECtraded 2026-10-06
917
$7.6K
+11.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 25, 2026.
  • The trade is 0.7% of the 126,854 shares held after it.
  • 2 other insiders sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Violette Shelia M. sold about $7.6K of QTTB on Oct 6, 2026; 2 other insiders sold within 30 days and 45 funds added in the latest 13F quarter.
Kalowski Lee
CFO and President
SELL
2026-10-14 SECtraded 2026-10-06
1,301
$10.8K
+11.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 25, 2026.
  • The trade is 0.9% of the 137,170 shares held after it.
  • 2 other insiders sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and President Kalowski Lee sold about $10.8K of QTTB on Oct 6, 2026; 2 other insiders sold within 30 days and 45 funds added in the latest 13F quarter.
Morrison Jodie Pope
CEO
SELL
2026-08-27 SECtraded 2026-08-25
9,845
$163.0K
-42.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 25, 2026.
  • The trade is 2.9% of the 343,259 shares held after it.
  • 2 other insiders sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Morrison Jodie Pope sold about $163.0K of QTTB on Aug 25, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 45 funds added in the latest 13F quarter.
Kalowski Lee
CFO and President
SELL
2026-08-27 SECtraded 2026-08-25
3,972
$65.8K
-42.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 25, 2026.
  • The trade is 2.9% of the 138,471 shares held after it.
  • 2 other insiders sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and President Kalowski Lee sold about $65.8K of QTTB on Aug 25, 2026; 2 other insiders sold within 30 days and 45 funds added in the latest 13F quarter.
21 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 16 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$29.7M over 180 days
-$320.4K over 90 days · +$30.0M of it by a 10%+ holder
more than 98% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
45 funds bought in last quarter
below 55% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
55.5% net margin
more than 96% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
36.7% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
more than 86% of Pharma & Biotech
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 14CEO Morrison Jodie Pope sold $26.8K (Oct 6)
Oct 14CFO and President Kalowski Lee sold $10.8K (Oct 6)
Oct 14Chief Scientific Officer Violette Shelia M. sold $7.6K (Oct 6)

Watch QTTB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+226.4%12M
-27%+217%+462%+707%2025-102025-122026-022026-042026-062026-082026-10 2026-05-28 · Xu Diyong bought $10.0M2026-05-28 · OrbiMed Capital GP VII LLC bought $10.0M2026-05-28 · Xu Diyong bought $5.0M2026-05-28 · OrbiMed Capital GP VII LLC bought $5.0M2026-08-25 · Morrison Jodie Pope sold $163.0K2025-12-02 · Morrison Jodie Pope sold $77.9K2026-08-25 · Kalowski Lee sold $65.8K2026-08-25 · Violette Shelia M. sold $46.3K2026-02-25 · Morrison Jodie Pope sold $44.6K2025-12-02 · Kalowski Lee sold $31.4K2026-10-06 · Morrison Jodie Pope sold $26.8K2026-02-25 · Kalowski Lee sold $18.0K2026-02-25 · Violette Shelia M. sold $12.7K2026-10-06 · Kalowski Lee sold $10.8K2026-10-06 · Violette Shelia M. sold $7.6K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns QTTB: institutional holders (13F)

13F holdings, latest reported quarter
ORBIMED ADVISORS LLC
4,127,987 sh
$52.6M
Boxer Capital Management, LLC
3,149,310 sh
$40.1M
Atlas Venture Life Science Advisors, LLC
2,717,106 sh
$34.6M
BVF INC/IL
2,350,000 sh
$29.9M
RA CAPITAL MANAGEMENT, L.P.
2,332,457 sh
$29.7M

Congress trades in QTTB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

QTTB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

QTTB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$441.0K position · as of 2026-06-30
0.4%
iShares Micro-Cap ETF
$375.4K position · as of 2026-06-30
0.0%
Small-Cap Value Portfolio
$79.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$25.0K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Value ETF
$1.4M position · as of 2026-05-31
0.0%
Column Small Cap Fund
$21.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $29.7M bought by insiders over 180 days, 45 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

QTTB financials

Net margin
55.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2024-01-01 to 2024-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
long-term debt only, 2024-12-31 (18 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
+72.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+37.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
invested capital is zero or negative
Return on capital employed
+26.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
2.76x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$151.2M
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term debt only, 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$53.7M$0$1.2M$3.2M
Operating income$16.9M-$66.1M-$48.3M-$133.3M
Net income$29.8M-$47.7M-$53.7M-$5.0M
EPS (diluted)2.42-6.58-153.96-0.09
Operating cash flow-$33.5M-$67.7M-$18.7M-$113.7M
Cash$48.3M$78.0M$25.6M$34.0M
Long-term debtn/a$0$38.6Mn/a
SEC XBRL, fiscal years, as known on 2026-10-27

QTTB Stock Sonar score 5/7 axes

Find similar shapesCompare

QTTB ranks highest on financial health (99th percentile) and profitability (95th), and lowest on risk and compliance (26th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
95
Inputs
  • Return on equity+72.1% · 95 pct, sector of 545
  • Return on assets+37.1% · 95 pct, sector of 691
  • Return on invested capitalinvested capital is zero or negative
  • Return on capital employed+26.0% · 96 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Insider conviction
89
Inputs
  • Net Form 4 buying (codes P and S), 180d$29.7M · 98 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
45
Inputs
  • Funds adding, latest quarter45 · 45 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
26
Inputs
  • Short interest, % of float+36.7% · 2 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+10.5% · 50 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

QTTB filings, in plain words

Are Q32 Bio insiders buying or selling QTTB?

In the 180 days to 2026-10-27, Q32 Bio insiders were net buyers, a net $29.7M: $30.0M of purchases and $320.4K of sales reported on Form 4, by 2 buyers and 3 sellers.

Read the full summary

In the 180 days to 2026-10-27, Q32 Bio insiders were net buyers of QTTB, a net $29.7M across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. Most of that figure, $30.0M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies